Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Tania Jain, MBBS

Assistant Professor of Oncology
Director, Immune Effector Cell Therapy Program
Division of Hematological Malignancies and Blood or Marrow Transplantation
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Disclosures

Participation by Dr Jain does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Tania Jain, MBBS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Bristol Myers Squibb Company; CTI BioPharma; Incyte Corporation; Kite Pharma, Inc.
Research funding from: CTI BioPharma; Incyte Corporation; Syneo

Andrew S. Artz, MD, MS

Professor
Department of Hematology & Hematopoietic Cell Transplantation
Director
Aging and Blood Cancers Program
City of Hope
Duarte, California

Disclosures

Andrew S. Artz, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Magenta
Research funding from: Jasper; Magenta

James M. Foran, MD, FRCPC

Professor of Medicine
Division of Hematology & Medical Oncology
Mayo Clinic College of Medicine and Science
Chair, Acute Leukemia & Myeloid Neoplasms Disease
Mayo Clinic Comprehensive Cancer Center
Jacksonville, Florida

Disclosures

James M. Foran, MD, FRCPC, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; CTI BioPharma; Daichi Sankyo; Novartis; Servier
Research funding from: Actinium; Astellas Pharma, Inc.; Astex; Celgene Corporation; DISC Medicine; Pfizer, Inc.; Roivant; Sellas
Owns stock (privately owned) in: Aurinia Pharmaceuticals, Inc.

Sergio A. Giralt, MD, FACP, FASTCT

Professor of Medicine
Weill Cornell Medical College
Deputy Division Head
Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Sergio A. Giralt, MD, FACP, FASTCT, has the following relevant financial relationships:
Consultant or advisor for: Actinium; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Janssen; Omeros; Pfizer, Inc.; Sanofi; Takeda
Research funding from: Actinium; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Jazz Pharmaceuticals; Janssen; Omeros; Pfizer, Inc.; Sanofi

Editor

Heather P. Friedman, MPH

Medical Education Director, Medscape, LLC

Disclosures

Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Building New Bridges to Transplant: A Focus on Emerging Bridging Strategies in Acute Myeloid Leukemia

Authors: Tania Jain, MBBS; Andrew S. Artz, MD, MS; James M. Foran, MD, FRCPC; Sergio A. Giralt, MD, FACP, FASTCT
CME / ABIM MOC Released: 3/27/2023
Valid for credit through: 3/27/2024

Start Activity

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.75 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, including transplant specialists and other clinicians who treat patients with AML.

The goal of this activity is for hematology/oncology and transplant specialists to be better able to understand recent data on current and emerging hematopoietic stem cell transplantation (HSCT) bridging strategies for acute myeloid leukemia, including novel agents and targeted radioimmunotherapies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data around new/emerging HSCT bridging strategies for AML 
- Patients who may be candidates for emerging HSCT bridging strategies in AML
Demonstrate greater confidence in their ability to
- Assess the potential implication of novel HSCT bridging strategies in AML

Disclosures

Faculty

Tania Jain, MBBS

Assistant Professor of Oncology
Director, Immune Effector Cell Therapy Program
Division of Hematological Malignancies and Blood or Marrow Transplantation
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Disclosures

Participation by Dr Jain does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Tania Jain, MBBS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Bristol Myers Squibb Company; CTI BioPharma; Incyte Corporation; Kite Pharma, Inc.
Research funding from: CTI BioPharma; Incyte Corporation; Syneo

Andrew S. Artz, MD, MS

Professor
Department of Hematology & Hematopoietic Cell Transplantation
Director
Aging and Blood Cancers Program
City of Hope
Duarte, California

Disclosures

Andrew S. Artz, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Magenta
Research funding from: Jasper; Magenta

James M. Foran, MD, FRCPC

Professor of Medicine
Division of Hematology & Medical Oncology
Mayo Clinic College of Medicine and Science
Chair, Acute Leukemia & Myeloid Neoplasms Disease
Mayo Clinic Comprehensive Cancer Center
Jacksonville, Florida

Disclosures

James M. Foran, MD, FRCPC, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; CTI BioPharma; Daichi Sankyo; Novartis; Servier
Research funding from: Actinium; Astellas Pharma, Inc.; Astex; Celgene Corporation; DISC Medicine; Pfizer, Inc.; Roivant; Sellas
Owns stock (privately owned) in: Aurinia Pharmaceuticals, Inc.

Sergio A. Giralt, MD, FACP, FASTCT

Professor of Medicine
Weill Cornell Medical College
Deputy Division Head
Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Sergio A. Giralt, MD, FACP, FASTCT, has the following relevant financial relationships:
Consultant or advisor for: Actinium; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Janssen; Omeros; Pfizer, Inc.; Sanofi; Takeda
Research funding from: Actinium; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Jazz Pharmaceuticals; Janssen; Omeros; Pfizer, Inc.; Sanofi

Editor

Heather P. Friedman, MPH

Medical Education Director, Medscape, LLC

Disclosures

Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Building New Bridges to Transplant: A Focus on Emerging Bridging Strategies in Acute Myeloid Leukemia

Authors: Tania Jain, MBBS; Andrew S. Artz, MD, MS; James M. Foran, MD, FRCPC; Sergio A. Giralt, MD, FACP, FASTCTFaculty and Disclosures

CME / ABIM MOC Released: 3/27/2023

Valid for credit through: 3/27/2024

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Tania Jain, MBBS

Andrew S. Artz, MD, MS

James M. Foran, MD, FRCPC

Sergio A. Giralt, MD, FACP, FASTCT

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

CME / ABIM MOC

Building New Bridges to Transplant: A Focus on Emerging Bridging Strategies in Acute Myeloid Leukemia

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Tania Jain, MBBS

Andrew S. Artz, MD, MS

James M. Foran, MD, FRCPC

Sergio A. Giralt, MD, FACP, FASTCT

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Building New Bridges to Transplant: A Focus on Emerging Bridging Strategies in Acute Myeloid Leukemia

Educational Impact Challenge